How They Work HOW DO ANTIDIABETIC GLUCAGON-LIKE PEPTIDE-1 AGONISTS WORK? HOW ARE ANTIDIABETIC GLUCAGON-LIKE PEPTIDE-1 AGONISTS USED? WHAT ARE SIDE EFFECTS OF ANTIDIABETIC GLUCAGON-LIKE PEPTIDE-1 AGONISTS? WHAT ARE NAMES OF ANTIDIABETIC GLUCAGON-LIKE PEPTIDE-1 AGONISTS? The GLP-1 receptor agonist drug class that has been updated include semaglutide (Ozempic, Rybelsus, Wegovy); liraglutide (Saxenda, Victoza); and MedicGLP Support the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 tirzepatide (Mounjaro, Zepbound). The FDA has received rare postmarketing reports of pulmonary aspiration in patients taking GLP-1 receptor agonists who were undergoing elective surgeries or procedures that required deep sedation or general anesthesia, in spite of following pre-operative fasting as recommended. Available data are insufficient to recommend whether modifying the pre-operative fasting recommendations, or discontinuing the GLP-1 receptor agonists temporarily can reduce the risk of pulmonary aspiration during deep sedation and anesthesia. Healthcare providers should apprise patients of the risk for pulmonary aspiration and advise them to inform if they are taking GLP-1 receptor agonists, if they plan to undergo any elective surgery or other medical procedures that require deep sedation or general anesthesia.
FDA has evaluated reports of suicidal thoughts or actions in patients treated with GLP-1 agonists. Preliminary evaluation has shown no evidence suggesting the use of GLP-1 agonists causes suicidal thoughts or actions. FDA reviews of the clinical trials, including large outcome studies and observational studies, did not find an association between use of GLP1 agonists and the occurrence of suicidal thoughts or actions. Owing to the small number of suicidal thoughts or actions observed in both treated patients and in comparative control groups, the FDA cannot definitively rule out that a small risk may exist; therefore, FDA is continuing to investigate this issue. Instruct patients not to stop taking GLP-1 agonists without first consulting a healthcare professional, as stopping these medicines may worsen their condition. Patients should contact their healthcare professional if new or worsening depression, suicidal thoughts, or any unusual changes in mood or behavior develops. HOW DO ANTIDIABETIC GLUCAGON-LIKE PEPTIDE-1 AGONISTS WORK? Antidiabetic glucagon-like peptide-1 agonists (also known as GLP-1 agonists) are a class of drugs used with a proper diet and exercise to control high blood sugar in people with type 2 diabetes mellitus (T2DM) and obesity.
T2DM is a long-term medical condition in which the body does not use insulin normally and, therefore, cannot control the amount of sugar in the blood. Controlling high blood sugar helps in preventing kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems and may also reduce the risk of a heart attack or stroke. Obesity is an abnormal or excessive fat accumulation that presents a health risk. A body mass index (BMI is calculated by considering a person’s weight and height to measure body size) of more than 25 is considered overweight and more than 30 is considered obese. GLP-1 agonists are synthetic (man-made) hormones that resemble and act like GLP-1 which is one of the gut hormones involved in controlling the blood sugar. GLP-1 agonists are available as injectable powder for suspension and a solution (liquid) in a prefilled dosing pen to be injected subcutaneously (under the skin) in the stomach, thigh, or upper arm. They belong to a class of drugs called "incretin mimetics" because these drugs mimic the effects of incretins.
Incretins are hormones that are produced and released into the blood by the intestine in response to food. GLP-1 is an incretin, one of the gut hormones, involved in controlling blood sugar, mainly acting on the insulin that the body produces after meals. HOW ARE ANTIDIABETIC GLUCAGON-LIKE PEPTIDE-1 AGONISTS USED? Obesity/weight management: adjunctive therapy to a reduced calorie diet and increased physical activity for chronic weight management in adults with a BMI of ≥30 kg/m2 (obese) or a BMI of ≥27 kg/m2 (overweight) who have at least one weight-related condition (hypertension, T2DM, dyslipidemia). WHAT ARE SIDE EFFECTS OF ANTIDIABETIC GLUCAGON-LIKE PEPTIDE-1 AGONISTS? Information contained herein is not intended to cover all possible side effects, precautions, warnings, drug interactions, allergic reactions, or adverse effects. Check with your doctor or pharmacist to make sure these drugs do not cause any harm when you take them along with other medicines. Never stop taking your medication and never change your dose or frequency without consulting your doctor.
Science continues to prove that the old adage "you are what you eat" is profoundly true. This is because you have trillions of microorganisms living in your gut, which are directly responsible for nearly every aspect of your health. These microbes make up what’s called your "gut microbiota." They are especially influential in determining your likelihood of gaining excessive weight, MedicGLP becoming obese, and developing obesity-related diseases like diabetes, heart disease, and premature death. The gut microbiome (the expressed genes of your gut microbiota) plays a major role in your metabolism through energy production, storage, MedicGLP Support and expenditure. So, it’s no surprise that science has found a strong connection between gut microbiome imbalance and metabolic syndrome. Yikes! If you have the wrong mix of microbes, it could be making it tough for you to get your health on track! Did you know: Medic GLP Website Scientists can actually look at your gut microbiome composition and tell with 90% accuracy if you are obese or lean. That’s pretty impressive, isn’t it?